Skip to content 
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company engaged in inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. The Company's pipeline is focused on treating pulmonary fibrosis. It has three approved oral antifibrotic therapies for pulmonary fibrosis: pirfenidone; nintedanib, and nerandomilast. Its clinically advanced candidates, AP01 and AP02, are inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis, respectively. It has completed ATLAS, a Phase Ib clinical trial of AP01 in patients with IPF. AP02 is being evaluated in AURA, a global Phase II clinical trial for the treatment of IPF. It is also advancing AP03 into a Phase I clinical trial. AP03 is a fixed-dose combination of inhaled pirfenidone, and nintedanib designed to deliver dual antifibrotic mechanisms with the potential for additive or synergistic benefit. more
| Dec '24 | Dec '25 | |||||
|---|---|---|---|---|---|---|
| Total Revenue | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Cost of Revenue | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Gross Profit | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Gross Margin | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Operating Expenses | 57.12M | 91.29M | [{"date":"2024-12-31","value":62.57,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |||
| Operating Income | (57.12M) | (91.29M) | [{"date":"2024-12-31","value":-5712100000,"profit":false},{"date":"2025-12-31","value":-9129200000,"profit":false}] | |||
| Total Non-Operating Income/Expense | 7.38M | 6.09M | [{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":82.53,"profit":true}] | |||
| Pre-Tax Income | (49.74M) | (85.20M) | [{"date":"2024-12-31","value":-4974400000,"profit":false},{"date":"2025-12-31","value":-8520400000,"profit":false}] | |||
| Income Taxes | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Income After Taxes | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Income From Continuous Operations | (49.74M) | (85.20M) | [{"date":"2024-12-31","value":-4974400000,"profit":false},{"date":"2025-12-31","value":-8520400000,"profit":false}] | |||
| Income From Discontinued Operations | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
| Net Income | (49.74M) | (85.20M) | [{"date":"2024-12-31","value":-4974400000,"profit":false},{"date":"2025-12-31","value":-8520400000,"profit":false}] | |||
| EPS (Diluted) | - | - | [{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |||
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| AVLN | |
|---|---|
| ROA (LTM) | -41.74% |
| ROE (LTM) | -68.34% |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| AVLN | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 0.00 |
| EV/R | 0.00 |
| EV/Ebitda | NM |
Avalyn Pharma (AVLN) share price today is $27.33
Yes, Indians can buy shares of Avalyn Pharma (AVLN) on Vested. To buy
Yes, you can purchase fractional shares of Avalyn Pharma (AVLN) via the Vested app. You can start investing in Avalyn Pharma (AVLN) with a minimum investment of $1.
You can invest in shares of Avalyn Pharma (AVLN) via Vested in three simple steps:
The 52-week high price of Avalyn Pharma (AVLN) is $30.67. The 52-week low price of Avalyn Pharma (AVLN) is $25.05.
The price-to-earnings (P/E) ratio of Avalyn Pharma (AVLN) is
The price-to-book (P/B) ratio of Avalyn Pharma (AVLN) is 0.00
The dividend yield of Avalyn Pharma (AVLN) is 0.00%
The market capitalization of Avalyn Pharma (AVLN) is $1.13B
The stock symbol (or ticker) of Avalyn Pharma is AVLN
Consider the share price of Avalyn Pharma as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Avalyn Pharma has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Avalyn Pharma shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Avalyn Pharma stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Avalyn Pharma and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Avalyn Pharma stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
